BID regulation by p53 contributes to chemosensitivity

Nature Cell Biology

Volumn 4, Issue 11, 2002, Pages 842-849

  Sax, Joanna K ^a   Fei, Peiwen ^a   Murphy, Maureen E ^b   Bernhard, Eric ^a   Korsmeyer, Stanley J ^c   El Deiry, Wafik S ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b FOX CHASE CANCER CENTER   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOXORUBICIN; FLUOROURACIL; MESSENGER RNA; NUCLEOTIDE DERIVATIVE; PROTEIN BCL 2; PROTEIN BID; PROTEIN P53;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL CYCLE; CELL DEATH; CHEMOSENSITIVITY; CHEMOTHERAPY; COLON MUCOSA; CONTROLLED STUDY; DNA DAMAGE; DNA RESPONSIVE ELEMENT; EMBRYO; FEMALE; FIBROBLAST; GAMMA IRRADIATION; GENE EXPRESSION; GENE LOCUS; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN FAMILY; REPORTER GENE; SPLEEN; TRANSACTIVATION; TRANSCRIPTION REGULATION;

ADENOVIRIDAE; ANIMALS; ANNEXIN A5; APOPTOSIS; BH3 INTERACTING DOMAIN DEATH AGONIST PROTEIN; BLOTTING, NORTHERN; BLOTTING, WESTERN; CARRIER PROTEINS; CELL DEATH; CELL LINE; CELL SEPARATION; CHROMATIN; COLON; COLORING AGENTS; DNA DAMAGE; DNA, COMPLEMENTARY; DOXORUBICIN; EPITHELIUM; FEMALE; FIBROBLASTS; FLOW CYTOMETRY; FLUOROURACIL; GAMMA RAYS; GENE EXPRESSION REGULATION; HUMANS; IN SITU HYBRIDIZATION; LUCIFERASES; MICE; MODELS, GENETIC; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PLASMIDS; PRECIPITIN TESTS; PROTEIN CONFORMATION; RNA, MESSENGER; SPLEEN; TEMPERATURE; TRANSCRIPTION, GENETIC; TUMOR SUPPRESSOR PROTEIN P53;

ANIMALIA;

EID: 85006263913     PISSN: 14657392     EISSN: None     Source Type: Journal    
DOI: 10.1038/ncb866     Document Type: Article

References (50)

1. Ryan, K. M., Phillips, A. C. & Vousden, K. H. Regulation and function of the p53 tumor suppressor protein. Curr. Opin. Cell Biol. 13, 332-337 (2001).
2. El-Deiry, W. S. Insights into cancer therapeutic design based on p53 and TRAIL receptor signaling. Cell Death Differ. 8, 1066-1075 (2001).
3. El-Deiry, W. S. et al. WAF1, a potential mediator of p53 tumor suppression. Cell 75, 817-825 (1993).
4. Attardi, L. D. et al. PERP, an apoptosis-associated target of p53, is a novel member of the PMP-22/gas3 family. Genes Dev. 14, 704-718 (2000).
5. Lin, Y., Ma, W. & Benchimol, S. Pidd, a new death-domain-containing protein, is induced by p53 and promotes apoptosis. Nature Genet. 26, 122-127 (2000).
6. Miyashita, T. & Reed, J. C. Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell 80, 293-299 (1995).
7. Nakano, K. & Vousden, K. H. PUMA, a novel proapoptotic gene, is induced by p53. Mol. Cell 7, 683-694 (2001).
8. Oda, E. et al. Noxa, a BH3-only member of the Bcl-2 family and candidate mediator of p53-induced apoptosis. Science 288, 1053-1058 (2000).
9. Yu, J., Zhang, L., Hwang, P. M., Kinzler, K. W. & Vogelstein, B. PUMA induces the rapid apoptosis of colorectal cancer cells. Mol. Cell 7, 673-682 (2001).
10. Wu, G. S. et al. KILLER/DR5 is a DNA damage-inducible p53-regulated death receptor gene. Nature Genet. 17, 141-143 (1997).
11. Wu, G. S., Burns, T. F., Zhan, Y., Alnemri, E. S. & El-Deiry, W. S. Molecular cloning and functional analysis of the mouse homologue of the KILLER/DR5 tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) death receptor. Cancer Res. 59, 2770-2775 (1999).
12. Muller, M. et al. p53 activates the CD95 (APO-1/Fas) gene in response to DNA damage by anticancer drugs. J. Exp. Med. 188, 2033-2045 (1998).
13. Murphy, M. et al. Transcriptional repression by wild-type p53 utilizes histone deacetylases, mediated by interaction with mSin3a. Genes Dev. 13, 2490-2501 (1999).
14. Hoffman, W. H., Biade, S., Zilfou, J. T., Chen, J. & Murphy, M. Transcriptional repression of the anti-apoptotic survivin gene by wild type p53. J. Biol. Chem. 277, 3247-3257 (2002).
15. Adams, J. M. & Cory, S. The Bcl-2 protein family: arbiters of cell survival. Science 281, 1322-1326 (1998).
16. Wang, K., Yin, X. M., Chao, D. T., Milliman, C. L. & Korsmeyer, S. J. BID: a novel BH3 domain-only death agonist. Genes Dev. 10, 2859-2869 (1996).
17. Li, H., Zhu, H., Xu, C. J. & Yuan, J. Cleavage of BID by caspase 8 mediates the mitochondrial damage in the Fas pathway of apoptosis. Cell 94, 491-501 (1998).
18. Luo, X., Budihardjo, I., Zou, H., Slaughter, C. & Wang, X. Bid, a Bcl2 interacting protein, mediates cytochrome c release from mitochondria in response to activation of cell surface death receptors. Cell 94, 481-490 (1998).
19. Zha, J., Weiler, S., Oh, K. J., Wei, M. C. & Korsmeyer, S. J. Posttranslational N-myristoylation of BID as a molecular switch for targeting mitochondria and apoptosis. Science 290, 1761-1765 (2000).
20. Wei, M. C. et al. tBID, a membrane-targeted death ligand, oligomerizes BAK to release cytochrome c. Genes Dev. 14, 2060-2071 (2000).
21. Wei, M. C. et al. Proapoptotic BAX and BAK: a requisite gateway to mitochondrial dysfunction and death. Science 292, 727-730 (2001).
22. L prevents this release but not tumor necrosis factor-R1/Fas death. J. Biol. Chem. 274, 1156-1163 (1999).
23. Yin, X. M. et al. Bid-deficient mice are resistant to Fas-induced hepatocellular apoptosis. Nature 400, 886-891 (1999).
24. Scaffidi, C. et al. Two CD95 (APO-1/Fas) signaling pathways. EMBO J. 17, 1675-1687 (1998).
25. Scorrano, L. et al. A distinct pathway remodels mitochondrial cristae and mobilizes cytochrome c during apoptosis. Dev. Cell 2, 55-67 (2002).
26. Harvey, D. M. & Levine, A. J. p53 alteration is a common event in the spontaneous immortalization of primary BALB/c murine embryo fibroblasts. Genes Dev. 5, 2375-2385 (1991).
27. Chen, J., Wu, X., Lin, J. & Levine, A. J. mdm-2 inhibits the G1 arrest and apoptosis functions of the p53 tumor suppressor protein. Mol. Cell. Biol. 16, 2445-2452 (1996).
28. Wang, Y. et al. Reconstitution of wild-type p53 expression triggers apoptosis in a p53-negative v-myc retrovirus-induced T-cell lymphoma line. Cell Growth Differ. 4, 467-473 (1993).
29. Pritchard, D. M., Potten, C. S., Korsmeyer, S. J., Roberts, S. & Hickman, J. A. Damage-induced apoptosis in intestinal epithelia from bcl-2-null and bax-null mice: investigations of the mechanistic determinants of epithelial apoptosis in vivo. Oncogene 18, 7287-7293 (1999).
30. Lowe, S. W., Schmitt, E. M., Smith, S. W., Osborne, B. A. & Jacks, T. p53 is required for radiation-induced apoptosis in mouse thymocytes. Nature 362, 847-849 (1993).
31. Midgley, C. A. et al. Coupling between gamma irradiation, p53 induction and the apoptotic response depends upon cell type in vivo. J. Cell Sci. 108, 1843-1848 (1995).
32. Burns, T. F., Bernhard, E. J. & El-Deiry, W. S. Tissue specific expression of p53 target genes suggests a key role for KILLER/DR5 in p53-dependent apoptosis in vivo. Oncogene 20, 4601-4612 (2001).
33. Wang, K. et al. BID, a proapoptotic BCL-2 family member, is localized to mouse chromosome 6 and human chromosome 22q11. Genomics 53, 235-238 (1998).
34. El-Deiry, W. S., Kern, S. E., Pietenpol, J. A., Kinzler, K. W. & Vogelstein, B. Definition of a consensus binding site for p53. Nature Genet. 1, 45-49 (1992).
35. Vousden, K. H. & Lu, X. Live or let die: The cell's response to p53. Nature Rev. Cancer 2, 594-604 (2002).
36. Kaeser, M. D. & Iggo, R. D. From the cover: chromatin immunoprecipitation analysis fails to support the latency model for regulation of p53 DNA binding activity in vivo. Proc. Natl Acad. Sci. USA 99, 95-100 (2002).
37. Oda, K. et al. p53AIP1, a potential mediator of p53-dependent apoptosis, and its regulation by Ser-46-phosphorylated p53. Cell 102, 849-862 (2000).
38. Costanzo, A. et al. DNA damage-dependent acetylation of p73 dictates the selective activation of apoptotic target genes. Mol. Cell 9, 175-186 (2002).
39. Bunz, F. et al. Disruption of p53 in human cancer cells alters the responses to therapeutic agents. J. Clin. Invest. 104, 263-269 (1999).
40. MacLachlan, T. K. & El-Deiry, W. S. Apoptotic threshold is lowered by p53 transactivation of caspase-6. Proc. Natl Acad. Sci. USA 99, 9492-9497 (2002).
41. Moroni, M. C. et al. Apaf-1 is a transcriptional target for E2F and p53. Nature Cell Biol. 3, 552-558 (2001).
42. Zeng, Y. X. & El-Deiry, W. S. Regulation of p21WAF1/CIP1 expression by p53- independent pathways. Oncogene 12, 1557-1564 (1996).
43. Sax, J. K., Dash, B. C., Hong, R., Dicker, D. T. & El-Deiry, W. S. The cyclin-dependent kinase inhibitor butyrolactone is a potent inhibitor of p21(WAF1/CIP1) expression. Cell Cycle 1, 90-96 (2002).
44. Kadkol, S., Juang, J. & Wu, T. C. in Tumor Suppressor Genes: Regulations, Functions and Medicinal Applications Vol. 2 (ed. El-Deiry, W. S.) (Humana Press, Totowa, NJ, 2003).
45. WAF1/CIP1, Nature 389, 187-190 (1997).
46. MacLachlan, T. K. et al. BRCA1 effects on the cell cycle and the DNA damage response are linked to altered gene expression. J. Biol. Chem. 275, 2777-2785 (2000).
47. Pietenpol, J. A. et al. Sequence-specific transcriptional activation is essential for growth suppression by p53. Proc. Natl Acad. Sci. USA 91, 1998-2002 (1994).
48. Zeng, Y. X., Somasundaram, K., Prabhu, N. S., Krishnadasan, R. & El-Deiry, W. S. Detection and analysis of living, growth-inhibited mammalian cells following transfection. Biotechniques 23, 88-94 (1997).
49. Takimoto, R. & El-Deiry, W. S. Wild-type p53 transactivates the KILLER/DR5 gene through an intronic sequence-specific DNA-binding site. Oncogene 19, 1735-1743 (2000).
50. Szak, S. T., Mays, D. & Pietenpol, J. A. Kinetics of p53 binding to promoter sites in vivo. Mol. Cell. Biol. 21, 3375-3386 (2001).